Aukes AM, De Groot JC, Wiegman MJ, Aarnoudse JG, Sanwikarja GS, Zeeman GG. Long-term cerebral imaging after pre-eclampsia. BJOG. 2012;119:1117 1122. 188. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation. 2010;122:579 584. 189. Berks D, Hoedjes M, Raat H, Duvekot J, Steegers E, Habbema J. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG. 2013;120:924 931. 190. Young B, Hacker MR, Rana S. Physicians knowledge of future vas- cular disease in women with preeclampsia. Hypertens Pregnancy. 2012;31:50 58. 191. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162 170. 192. Star M, Flaster M. Advances and controversies in the management of cerebral venous thrombosis. Neurol Clin. 2013;31:765 783. 193. Coutinho JM, Ferro JM, Canh o P, Barinagarrementeria F, Cant C, Bousser MG, Stam J. Cerebral venous and sinus thrombosis in women. Stroke. 2009;40:2356 2361. 194. Ferro JM, Canh o P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus throm- bosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664 670. 195. Ferro JM, Correia M, Pontes C, Baptista MV, Pita F; Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport). Cerebral vein and dural sinus thrombosis in Portugal: 1980 1998. Cerebrovasc Dis. 2001;11:177 182. 196. Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J; Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport). Long- term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study. Cerebrovasc Dis. 2002;13:272 278. 197. Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cere- bral sinus-venous thrombosis. Circulation. 2010;121:2740 2746. 198. Coutinho JM, Zuurbier SM,Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43:3375 3377. 199. Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Siragusa S, Kostal M, Palareti G, Sartori MT, Grandone E, Vedovati MC, Ageno W; for the CEVETIS (CErebral VEin Thrombosis International Study) Investigators. Long-term outcomes of patients with cerebral vein throm- bosis: a multicenter study [published correction appears in J Thromb Haemost. 2013;11:399]. J Thromb Haemost. 2012;10:1297 1302. 200. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY; on behalf of the American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cere- bral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158 1192. 201. deVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ, Camfield CS, David M, Humphreys P, Langevin P, MacDonald EA, Gillett J, Meaney B, Shevell M, Sinclair DB,Yager J; Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in chil- dren. N Engl J Med. 2001;345:417 423. 202. Ferro JM, Canh o P, Bousser MG, Stam J, Barinagarrementeria F; ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36:1927 1932. 203. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793 1797. 204. Bousser MG, Crassard I. Cerebral venous thrombosis, pregnancy and oral contraceptives. Thromb Res. 2012;130(suppl 1):S19 S22. 205. Ahrens I, Peter K, Lip GY, Bode C. Development and clinical appli- cations of novel oral anticoagulants, part I: clinically approved drugs. Discov Med. 2012;13:433 443. 206. Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamuly k K, Prins MH, Buller HR, van der Meer J. Selective test- ing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314 5322. 207. Alshekhlee A, Borhani Haghighi A, Cruz-Flores S. Response to letter by Coutinho et al regarding article, Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke. 2012;43:e23. 208. Borhani Haghighi A, Edgell RC, Cruz-Flores S, Feen E, Piriyawat P, Vora N, Callison RC, Alshekhlee A. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke. 2012;43:262 264. 209. Nasr DM, Brinjikji W, Cloft HJ, Saposnik G, Rabinstein AA. Mortality in cerebral venous thrombosis: results from the National Inpatient Sample database. Cerebrovasc Dis. 2013;35:40 44. 210. Lanska DJ, Kryscio RJ. Peripartum stroke and intracranial venous thrombosis in the National Hospital Discharge Survey. Obstet Gynecol. 1997;89:413 418. 211. Wilterdink JL, Easton JD. Cerebral ischemia in pregnancy. Adv Neurol. 2002;90:51 62. 212. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:844S 886S. 213. Ciron J, Goden che G, Vandamme X, Rosier MP, Sharov I, Mathis S, Larrieu D, Neau JP. Obstetrical outcome of young women with a past history of cerebral venous thrombosis. Cerebrovasc Dis. 2013;36:55 61. 214. Mosher WD, Jones J. Use of contraception in the United States: 1982 2008. Vital Health Stat 23. 2010;(29):1 44. 215. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72 78. 216. Chan W-S, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, Ginsberg JS. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence [published correction appears in Arch Intern Med. 2005;165:2040]. Arch Intern Med. 2004;164:741 747. 217. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863 3870. 218. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke. 2009;40:1059 1062. 219. Yang L, Kuper H, Sandin S, Margolis KL, Chen Z, Adami HO, Weiderpass E. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke. 2009;40:1050 1058. 220. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contracep- tives: results of an international, multicentre, case-control study. Lancet. 1996;348:498 505. 221. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet. 1996;348:505 510. 222. Wang C, Li Y, Li H, Sun T, Jin G, Sun Z, Zhou J, Ba L, Huang Z, Bai J. Increased risk of stroke in oral contraceptive users carried repli- cated genetic variants: a population-based case-control study in China. Hum Genet. 2012;131:1337 1344. 223. Chang CL, Donaghy M, Poulter N; World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study BMJ. 1999;318:13 18. 224. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der GraafY, Rosendaal FR,AlgraA. Risk ofArterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202 1208. 225. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213 1217. 226. Pruissen DM, Slooter AJ, Rosendaal FR, van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood. 2008;111:1282 1286. 227. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998 1005. 228. Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119:1555 1560. 229. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analy- sis: the Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10:1 110. 230. MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ. Probable migraine with visual aura and risk of isch- emic stroke: the Stroke Prevention in Young Women Study. Stroke. 2007;38:2438 2445. 231. Bousser MG, Conard J, Kittner S, de Lignieres B, MacGregor EA, Massiou H, Silberstein SD, Tzourio C; International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia. 2000;20:155 156. 232. Hickson SS, Miles KL, McDonnell BJ,Yasmin, Cockcroft JR, Wilkinson IB, McEniery CM; ENIGMA Study Investigators. Use of the oral Bushnell et al Guidelines for Prevention of Stroke in Women 1583 contraceptive pill is associated with increased large artery stiffness in young women: the ENIGMA study. J Hypertens. 2011;29:1155 1159. 233. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006;73:179 188. 234. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception. 2013;87:611 624. 235. Tepper NK, Curtis KM, Steenland MW, Marchbanks PA. Blood pressure measurement prior to initiating hormonal contraception: a systematic review. Contraception. 2013;87:631 638. 236. Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos- Holzmann I, Bruppacher R; Transnational Research Group on Oral Contraceptives and the Health of Young Women. Thromboembolic stroke in young women: a European case-control study on oral contra- ceptives. Contraception. 1998;57:29 37. 237. Lisabeth L, Bushnell C. Stroke risk in women: the role of menopause and hormone therapy [published correction appears in Lancet Neurol. 2012;11:125]. Lancet Neurol. 2012;11:82 91. 238. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012;19:272 277. 239. Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, Rosner B, Stampfer MJ.Age at natural menopause and risk of cardio- vascular disease. Arch Intern Med. 1999;159:1061 1066. 240. Choi SH, Lee SM, Kim Y, Choi NK, Cho YJ, Park BJ. Natural menopause and risk of stroke in elderly women. J Korean Med Sci. 2005;20:1053 1058. 241. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke. 2009;40:1044 1049. 242. Baba Y, Ishikawa S, Amagi Y, Kayaba K, Gotoh T, Kajii E. Premature menopause is associated with increased risk of cerebral infarction in Japanese women. Menopause. 2010;17:506 510. 243. de Leci ana MA, Egido JA, Fern ndez C, Mart nez-Vila E, Santos S, Morales A, Mart nez E, Pareja A, Alvarez-Sab n J, Casado I; PIVE Study Investigators of the Stroke Project of the Spanish Cerebrovascular Diseases Study Group. Risk of ischemic stroke and lifetime estrogen exposure. Neurology. 2007;68:33 38. 244. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd, Rocca WA. Increased cardiovascular mortality after early bilat- eral oophorectomy. Menopause. 2009;16:15 23. 245. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses Health Study. Obstet Gynecol. 2009;113:1027 1037. 246. Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J. 2011;32:745 750. 247. Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, Sarto GE, Robbins J, Phillips L, Martin LW, O Sullivan MJ, Jackson R, Rodabough RJ, Stefanick ML. Oophorectomy vs ovar- ian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women s Health Initiative Observational Study. Arch Intern Med. 2011;171:760 768. 248. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent dis- ease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016 1037. 249. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protec- tion or no effect? Maturitas. 2001;38:243 261. 250. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett- Connor E, Hulley SB. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638 642. 251. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243 1249. 252. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [published correction appears in JAMA. 2002;288:1064]. JAMA. 2002;288:49 57. 253. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women s Health Initiative randomized controlled trial. JAMA. 2004;291:1701 1712. 254. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J; WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women s Health Initiative. Circulation. 2006;113:2425 2434. 255. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA. 2002;288:321 333. 256. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; WHI Investigators. Effect of estro- gen plus progestin on stroke in postmenopausal women: the Women s Health Initiative: a randomized trial. JAMA. 2003;289:2673 2684. 257. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas. 2006;55:162 173. 258. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, K ber L, Jensen JE. Effect of hormone replacement therapy on car- diovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. 259. The Women s Health Initiative Study Group. Design of the Women s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61 109. 260. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus pro- gestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651 2662. 261. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women s Health Initiative Memory Study. Conjugated equine estrogens and inci- dence of probable dementia and mild cognitive impairment in post- menopausal women: Women s Health Initiative Memory Study. JAMA. 2004;291:2947 2958. 262. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J; for the Women s Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in post- menopausal women: Women s Health Initiative Memory Study. JAMA. 2004;291:2959 2968. 263. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators. Effect of estro- gen plus progestin on global cognitive function in postmenopausal women: the Women s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663 2672. 264. Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C. Postmenopausal hormone ther- apy and regional brain volumes: the WHIMS-MRI Study. Neurology. 2009;72:135 142. 265. Coker LH, Hogan PE, Bryan NR, Kuller LH, Margolis KL, Bettermann K, Wallace RB, Lao Z, Freeman R, Stefanick ML, Shumaker SA. Postmenopausal hormone therapy and subclinical cerebrovascular dis- ease: the WHIMS-MRI Study. Neurology. 2009;72:125 134. 266. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847 857. 267. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125 137. 268. Formoso G, Perrone E, Maltoni S, Balduzzi S, D Amico R, Bassi C, Basevi V, Marata AM, Magrini N, Maestri E. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012;2:CD008536. 269. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since meno- pause [published correction appears in JAMA. 2008;299:1426]. JAMA. 2007;297:1465 1477. 270. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hor- mone therapy and stroke: role of time since menopause and age at initia- tion of hormone therapy. Arch Intern Med. 2008;168:861 866. 271. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3 12. 272. Renoux C, Dell aniello S, Garbe E, Suissa S. Transdermal and oral hor- mone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519. 273. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommenda- tions. Ann Intern Med. 2012;157:104 113. 274. Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: per- spectives 10 years after the Women s Health Initiative trials. Climacteric. 2012;15:229 234. 275. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7:CD004143. 276. Nastri CO, Lara LA, Ferriani RA, Rosa ESAC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and post- menopausal women. Cochrane Database Syst Rev. 2013;6:CD009672. 277. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53:230 246. 278. Wolff s Headache and Other Head Pain. 7th ed. Silberstein SD, Lipton RB, Dalessio DJ, eds. New York, NY: Oxford University Press; 2001. 279. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123:612 624. 280. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914. 281. Kurth T, Diener HC. Migraine and stroke: perspectives for stroke physi- cians. Stroke. 2012;43:3421 3426. 282. Kurth T, Sch rks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009;73:581 588. 283. Sch rks M, Buring JE, Kurth T. Migraine, migraine features, and cardio- vascular disease. Headache. 2010;50:1031 1040. 284. Rist PM, Buring JE, Kase CS, Sch rks M, Kurth T. Migraine and func- tional outcome from ischemic cerebral events in women. Circulation. 2010;122:2551 2557. 285. Kurth T, Diener HC, Buring JE. Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women s Health Study. Cephalalgia. 2011;31:1106 1115. 286. Kurth T, Kase CS, Schurks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in women: prospective cohort study. BMJ. 2010;341:c3659. 287. Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009;338:b664. 288. Adeney KL, Williams MA, Miller RS, Frederick IO, Sorensen TK, Luthy DA. Risk of preeclampsia in relation to maternal history of migraine headaches. J Matern Fetal Neonatal Med. 2005;18:167 172. 289. Facchinetti F, Allais G, Nappi RE, D Amico R, Marozio L, Bertozzi L, Ornati A, Benedetto C. Migraine is a risk factor for hyperten- sive disorders in pregnancy: a prospective cohort study. Cephalalgia. 2009;29:286 292. 290. Sanchez SE, Qiu C, Williams MA, Lam N, Sorensen TK. Headaches and migraines are associated with an increased risk of preeclampsia in Peruvian women. Am J Hypertens. 2008;21:360 364. 291. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2000;56:142]. Neurology. 2000;55:754 762. 292. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americansbecomeoverweightorobese?Estimatingtheprogressionandcost of the US obesity epidemic. Obesity (Silver Spring). 2008;16:2323 2330. 293. Ford ES, Li C, Zhao G, Tsai J. Trends in obesity and abdominal obesity among adults in the United States from 1999 2008. Int J Obes (Lond). 2011;35:736 743. 294. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999 2008. JAMA. 2010;303:235 241. 295. Vague J. La differenciation sexuelle, feateur determinant des formes de l obesite [in French]. Presse Med. 1947;55:339 340. 296. Towfighi A, Zheng L, Ovbiagele B. Weight of the obesity epidemic: ris- ing stroke rates among middle-aged women in the United States. Stroke. 2010;41:1371 1375. 297. Bazzano LA, Gu D, Whelton MR, Wu X, Chen CS, Duan X, Chen J, Chen JC, He J. Body mass index and risk of stroke among Chinese men and women. Ann Neurol. 2010;67:11 20. 298. Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S. Body mass index, weight change and risk of stroke and stroke subtypes: the Japan Public Health Center-based prospective (JPHC) study. Int J Obes (Lond). 2011;35:283 291. 299. Kurth T, Gaziano JM, Rexrode KM, Kase CS, Cook NR, Manson JE, Buring JE. Prospective study of body mass index and risk of stroke in apparently healthy women. Circulation. 2005;111:1992 1998. 300. Hu G, Tuomilehto J, Silventoinen K, Sarti C, M nnist S, Jousilahti P. Body mass index, waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. Arch Intern Med. 2007;167:1420 1427. 301. Yatsuya H, Folsom AR, Yamagishi K, North KE, Brancati FL, Stevens J; Atherosclerosis Risk in Communities Study Investigators. Race- and sex-specific associations of obesity measures with ischemic stroke inci- dence in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2010;41:417 425. 302. Strazzullo P, D Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospec- tive studies with 2 million participants. Stroke. 2010;41:e418 e426. 303. Zhang X, Shu XO, Gao YT, Yang G, Li H, Zheng W. General and abdominal adiposity and risk of stroke in Chinese women. Stroke. 2009;40:1098 1104. 304. Lu M, Ye W, Adami HO, Weiderpass E. Prospective study of body size and risk for stroke amongst women below age 60. J Intern Med. 2006;260:442 450. 305. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277:1539 1545. 306. Wang C, LiuY,Yang Q, Dai X, Wu S, Wang W, Ji X, Li L, Fang X. Body mass index and risk of total and type-specific stroke in Chinese adults: results from a longitudinal study in China. Int J Stroke. 2013;8:245 250. 307. Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J, Back T. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke. 2008;39:3145 3151. 308. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE. Body mass index and the risk of stroke in men. Arch Intern Med. 2002;162:2557 2562. 309. Cornier MA, Despr s JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge MP, TowfighiA, Poirier P; on behalf of the American Heart Association Obesity Committee of the Council on Nutrition; PhysicalActivity and Metabolism; Council onArteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing, Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease, and Stroke Council. Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011;124:1996 2019. 310. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, Wright C, Giardina EG, DiTullio MR, Homma S, Paik MC. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke. 2008;39:30 35. 311. Wang J, Ruotsalainen S, Moilanen L, Lepist P, Laakso M, Kuusisto J. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland. Stroke. 2008;39:1078 1083. 312. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC; Northern Manhattan Stroke Study. Abdominal obesity and Bushnell et al Guidelines for Prevention of Stroke in Women 1585 risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke. 2003;34:1586 1592. 313. Furukawa Y, Kokubo Y, Okamura T, Watanabe M, Higashiyama A, Ono Y, Kawanishi K, Okayama A, Date C. The relationship between waist circumference and the risk of stroke and myocardial infarction in a Japanese urban cohort: the Suita study. Stroke. 2010;41:550 553. 314. Milionis HJ, Filippatos TD, Derdemezis CS, Kalantzi KJ, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. Eur J Neurol. 2007;14:762 769. 315. Towfighi A, Ovbiagele B. The impact of body mass index on mortality after stroke. Stroke. 2009;40:2704 2708. 316. Doehner W, Schenkel J,Anker SD, Springer J,Audebert HJ. Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial. Eur Heart J. 2013;34:268 277. 317. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed LM, Kent KM, Pichard AD, Suddath WO, Satler LF, Lindsay J Jr. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39:578 584. 318. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180 193. 319. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke. 2006;37:1060 1064. 320. Ninomiya JK, L Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarc- tion and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42 46. 321. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006;166:106 111. 322. Towfighi A, Ovbiagele B. Metabolic syndrome and stroke. Curr Diab Rep. 2008;8:37 41. 323. Wannamethee SG, ShaperAG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644 2650. 324. Takahashi K, Bokura H, Kobayashi S, Iijima K, Nagai A, Yamaguchi S. Metabolic syndrome increases the risk of ischemic stroke in women. Intern Med. 2007;46:643 648. 325. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Components of the metabolic syndrome and risk for first- ever acute ischemicnonembolicstrokeinelderlysubjects.Stroke.2005;36:1372 1376. 326. Li W, Ma D, Liu M, Liu H, Feng S, Hao Z, Wu B, Zhang S. Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies. Cerebrovasc Dis. 2008;25:539 547. 327. Kurth T, Moore SC, Gaziano JM, Kase CS, Stampfer MJ, Berger K, Buring JE. Healthy lifestyle and the risk of stroke in women. Arch Intern Med. 2006;166:1403 1409. 328. Rosito GA, D Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost. 2004;91:683 689. 329. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54:1847 1856. 330. Bakhai A. Adipokines: targeting a root cause of cardiometabolic risk. QJM. 2008;101:767 776. 331. Kraja AT, Province MA, Arnett D, Wagenknecht L, Tang W, Hopkins PN, Djouss L, Borecki IB. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab (Lond). 2007;4:28. 332. McLaughlin T, Deng A, Gonzales O, Aillaud M, Yee G, Lamendola C, Abbasi F, Connolly AJ, Sherman A, Cushman SW, Reaven G, Tsao PS. Insulin resistance is associated with a modest increase in inflammation in subcutaneous adipose tissue of moderately obese women. Diabetologia. 2008;51:2303 2308. 333. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self- fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913 919. 334. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439 1441. 335. Despr s JP. Targeting abdominal obesity and the metabolic syndrome to manage cardiovascular disease risk. Heart. 2009;95:1118 1124. 336. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348:2599 2608. 337. Liu S, Manson JE, Lee IM, Cole SR, Hennekens CH, Willett WC, Buring JE. Fruit and vegetable intake and risk of cardiovascular disease: the Women s Health Study. Am J Clin Nutr. 2000;72:922 928. 338. Huijbregts P, Feskens E, R s nen L, Fidanza F, Nissinen A, Menotti A, Kromhout D. Dietary pattern and 20 year mortality in elderly men in Finland, Italy, and The Netherlands: longitudinal cohort study. BMJ. 1997;315:13 17. 339. Mensink GB, Deketh M, Mul MD, Schuit AJ, Hoffmeister H. Physical activity and its association with cardiovascular risk factors and mortality. Epidemiology. 1996;7:391 397. 340. Lee IM, Paffenbarger RS Jr. Physical activity and stroke incidence: the Harvard Alumni Health Study. Stroke. 1998;29:2049 2054. 341. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288:1994 2000. 342. Berlin JA, Colditz GA. A meta-analysis of physical activity in the pre- vention of coronary heart disease. Am J Epidemiol. 1990;132:612 628. 343. Leon AS, Connett J. Physical activity and 10.5 year mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol. 1991;20:690 697. 344. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women: a prospective cohort study. Ann Intern Med. 1993;119:992 1000. 345. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269:232 236. 346. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994;154:169 175. 347. White IR, Altmann DR, Nanchahal K. Alcohol consumption and mor- tality: modelling risks for men and women at different ages. BMJ. 2002;325:191. 348. Liao Y, McGee DL, Cao G, Cooper RS. Alcohol intake and mortality: findings from the National Health Interview Surveys (1988 and 1990). Am J Epidemiol. 2000;151:651 659. 349. Towfighi A, Markovic D, Ovbiagele B. Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA. J Neurol Neurosurg Psychiatry. 2012;83:146 151. 350. Kontogianni MD, Liatis S, Grammatikou S, Perrea D, Katsilambros N, Makrilakis K. Changes in dietary habits and their association with meta- bolic markers after a non-intensive, community-based lifestyle interven- tion to prevent type 2 diabetes, in Greece: the DEPLAN study. Diabetes Res Clin Pract. 2012;95:207 214. 351. Khare MM, Carpenter RA, Huber R, Bates NJ, Cursio JF, Balmer PW, Nolen KN, Hudson H, Shippee SJ, Loo RK. Lifestyle intervention and cardiovascular risk reduction in the Illinois WISEWOMAN Program. J Womens Health (Larchmt). 2012;21:294 301. 352. Costa B, Barrio F, Cabr JJ, Pi ol JL, Cos X, Sol C, Bol bar B, Basora J, Castell C, Sol -Morales O, Salas-Salvad J, Lindstr m J, Tuomilehto J. Delaying progression to type 2 diabetes among high-risk Spanish indi- viduals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia. 2012;55:1319 1328. 353. Parekh S, Vandelanotte C, King D, Boyle FM. Design and baseline char- acteristics of the 10 Small Steps Study: a randomised controlled trial of an intervention to promote healthy behaviour using a lifestyle score and personalised feedback. BMC Public Health. 2012;12:179. 354. Vermunt PW, Milder IE, Wielaard F, de Vries JH, Baan CA, van Oers JA, Westert GP. A lifestyle intervention to reduce type 2 diabetes risk in Dutch primary care: 2.5-year results of a randomized controlled trial. Diabet Med. 2012;29:e223 231. 355. Kanaya AM, Santoyo-Olsson J, Gregorich S, Grossman M, Moore T, Stewart AL. The Live Well, Be Well study: a community-based, translational lifestyle program to lower diabetes risk factors in ethnic minority and lower-socioeconomic status adults. Am J Public Health. 2012;102:1551 1558. 356. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28:888 894. 357. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford MM, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489 2496. 358. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil- Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. Low-fat dietary pattern and risk of cardiovascular dis- ease: the Women s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655 666. 359. Parra-Medina D, Wilcox S, Salinas J, Addy C, Fore E, Poston M, Wilson DK. Results of the Heart Healthy and Ethnically Relevant Lifestyle trial: a cardiovascular risk reduction intervention for African American women attending community health centers. Am J Public Health. 2011;101:1914 1921. 360. Rankin P, Morton DP, Diehl H, Gobble J, Morey P, Chang E. Effectiveness of a volunteer-delivered lifestyle modification program for reducing car- diovascular disease risk factors. Am J Cardiol. 2012;109:82 86. 361. Ross R, Lam M, Blair SN, Church TS, Godwin M, Hotz SB, Johnson A, Katzmarzyk PT, L vesque L, MacDonald S. Trial of prevention and reduction of obesity through active living in clinical settings: a random- ized controlled trial. Arch Intern Med. 2012;172:414 424. 362. Estruch R, Ros E, Salas-Salvad J, Covas MI, Corella D, Ar s F, G mez- Gracia E, Ruiz-Guti rrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pint X, Basora J, Mu oz MA, Sorl JV, Mart nez JA, Mart nez-Gonz lez MA; PREDIMED Study Investigators. Primary pre- vention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279 1290. 363. Towfighi A, Cheng E, Valle N, Vickrey B. HEALS (Healthy Eating And Lifestyle After Stroke): a pilot trial of a multidisciplinary lifestyle inter- vention program. Clinicaltrials.gov identifier: NCT01550822. http:// clinicaltrials.gov/show/NCT01550822. Accessed February 21, 2013. 364. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901 1910. 365. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111 117. 366. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside NorthAmerica and Europe. Chest. 2012;142:1489 1498. 367. Shen AY, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, Brar SS, Chen W. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults: a cross-sectional study. J Natl Med Assoc. 2010;102:906 913. 368. Fuster V, Ryd n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Tarkington LG,Yancy CW. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269 e367. 369. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrilla- tion. Analysis and implications. Arch Intern Med. 1995;155:469 473. 370. Fonarow GC, Reeves MJ, Zhao X, Olson DM, Smith EE, Saver JL, Schwamm LH; Get With The Guidelines-Stroke Steering Committee and Investigators. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation. 2010;121:879 891. 371. Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH; Get With The Guidleines-Stroke Steering Committee and Investigators. Quality of care in women with ischemic stroke in the GWTG program. Stroke. 2009;40:1127 1133. 372. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012;307:1952 1958. 373. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103:2365 2370. 374. Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, Black S; Stroke Outcome Research Canada (SORCan) Working Group. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke. 2008;39:2310 2317. 375. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297 305. 376. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Stroke incidence on the east coast ofAustralia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2000;31:2087 2092. 377. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA; on behalf of the American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advi- sory for healthcare professionals from the American Heart Association/ American Stroke Association [published corrections appear in Stroke. 2013;44:e20 and Stroke. 2012;43:e181]. Stroke. 2012;43:3442 3453. 378. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864 2870. 379. Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ. The CHA2 -VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J. 2013;34:170 176. 380. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687 1691. 381. Friberg J, Scharling H, Gadsb ll N, Truelsen T, Jensen GB; Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol. 2004;94:889 894. 382. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012;344:e3522. 383. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the commu- nity: the Framingham Heart Study. JAMA. 2003;290:1049 1056. 384. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0 1: a nationwide cohort study. Thromb Haemost. 2012;107:1172 1179. 385. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263 272. 386. Fuster V, Ryd n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the manage- ment of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in Circulation. 2007;116:e138]. Circulation. 2006;114:e257 354. 387. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC); Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast Bushnell et al Guidelines for Prevention of Stroke in Women 1587 B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH;. Guidelines for the management of atrial fibrillation: the Task Force for the Management ofAtrial Fibrillation of the European Society of Cardiology (ESC): [published correction appears in Europace. 2011;13:1058]. Europace. 2010;12:1360 1420. 388. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, Mitchell LB, Verma A, Nattel S; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control [published correction appears in Can J Cardiol. 2012;28:396]. Can J Cardiol. 2012;28:125 136. 389. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and throm- boembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. 390. Sullivan RM, Zhang J, Zamba G, Lip GY, Olshansky B. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol. 2012;110:1799 1802. 391. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806 817. 391a.Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrilla- tion. N Engl J Med. 2011;365:981 992. 392. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus war- farin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363:1877]. N Engl J Med. 2009;361:1139 1151. 393. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883 891. 394. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharma- codynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47 59. 395. Duffull SB, Wright DF, Al-Sallami HS, Zufferey PJ, Faed JM. Dabigatran: rational dose individualisation and monitoring guidance is needed. N Z Med J. 2012;125:148 154. 396. PRADAXA [data sheet]. Manukau City, Auckland, New Zealand: Boehringer Ingelheim (N.Z.) Ltd; 2011. 397. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depres- sion after stroke: a systematic review of observational studies. Stroke. 2005;36:1330 1340. 398. Pan A, Okereke OI, Sun Q, Logroscino G, Manson JE, Willett WC, Ascherio A, Hu FB, Rexrode KM. Depression and incident stroke in women. Stroke. 2011;42:2770 2775. 399. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review [published correction appears in JAMA. 2011;306;2565]. JAMA. 2011;306:1241 1249. 400. Geller SE, Adams MG, Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. J Womens Health (Larchmt). 2006;15:1123 1131. 401. Goode PS, Fitzgerald MP, Richter HE, Whitehead WE, Nygaard I, Wren PA, Zyczynski HM, Cundiff G, Menefee S, Senka JM, Gao X, Weber AM; Pelvic Floor Disorders Network. Enhancing participation of older women in surgical trials. J Am Coll Surg. 2008;207:303 311. 402. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475 480. 403. MurthyVH, Krumholz HM, Gross CP. Participation in cancer clinical tri- als: race-, sex-, and age-based disparities. JAMA. 2004;291:2720 2726. 404. Burke JF, Brown DL, Lisabeth LD, Sanchez BN, Morgenstern LB. Enrollment of women and minorities in NINDS trials. Neurology. 2011;76:354 360. 405. NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research: Amended, October 2001. National Institutes of Health Web site. http:/grants1.nih.gov/grants/funding/ women_min/guidelines_amended_10_2001.htm. Accessed June 14, 2013. 406. Ramasubbu K, Gurm H, Litaker D. Gender bias in clinical trials: do double standards still apply? J Womens Health Gend Based Med. 2001;10:757 764. 407. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859 1869. 408. Tsang W, Alter DA, Wijeysundera HC, Zhang T, Ko DT. The impact of cardiovascular disease prevalence on women s enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med. 2012;27:93 98. 409. NorthAmerican Symptomatic Carotid EndarterectomyTrial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445 453. 410. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, Spence JD; North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339:1415 1425. 411. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351:1379 1387. 412. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421 1428. 413. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D; MRCAsymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarter- ectomy in patients without recent neurological symptoms: randomised controlled trial [published correction appears in Lancet. 2004;364:416]. Lancet. 2004;363:1491 1502. 414. Mas JL, Trinquart L, Leys D, Albucher JF, Rousseau H, Viguier A, Bossavy JP, Denis B, Piquet P, Garnier P,Viader F, Touz E, Julia P, Giroud M, Krause D, Hosseini H, Becquemin JP, Hinzelin G, Houdart E, H non H, Neau JP, Bracard S, Onnient Y, Padovani R, Chatellier G; EVA-3S Investigators. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol. 2008;7:885 892. 415. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H, Jansen O. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospec- tive, randomised trial [published correction appears in Lancet Neurol. 2009;8:135]. Lancet Neurol. 2008;7:893 902. 416. Brott TG, Hobson RW 2nd, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Meschia JF; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis [published corrections appear in N Engl J Med. 2010;363:198 and N Engl J Med. 2010;363:498]. N Engl J Med. 2010;363:11 23. 417. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD; for the ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Low- dose and high-dose acetylsalicylic acid for patients undergoing carotid end- arterectomy: a randomised controlled trial. Lancet. 1999;353:2179 2184. 418. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1 13. 419. CAPRIE Steering Committee. A randomised, blinded, trial of clopido- grel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329 1339. 420. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331 337. 421. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S; African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289:2947 2957. 422. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial [published correction appears in Lancet. 2007;369:274]. Lancet. 2006;367:1665 1673. 423. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahl f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended- release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238 1251. 424. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA; SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817 825. 425. Rothwell PM, Slattery J, Warlow CP. Clinical and angiographic predic- tors of stroke and death from carotid endarterectomy: systematic review. BMJ. 1997;315:1571 1577. 426. Kandiyil N, Altaf N, Hosseini AA, MacSweeney ST, Auer DP. Lower prevalence of carotid plaque hemorrhage in women, and its mediator effect on sex differences in recurrent cerebrovascular events. PLoS One. 2012;7:e47319. 427. Poisson SN, Johnston SC, Sidney S, Klingman JG, Nguyen-Huynh MN. Gender differences in treatment of severe carotid stenosis after transient ischemic attack. Stroke. 2010;41:1891 1895. 428. Marquardt L, Fairhead JF, Rothwell PM. Lower rates of intervention for symptomatic carotid stenosis in women than in men reflect differences in disease incidence: a population-based study. Stroke. 2010;41:16 20. 429. International Carotid Stenting Study Investigators; Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ, Lo TH, Gaines P, Dorman PJ, Macdonald S, Lyrer PA, Hendriks JM, McCollum C, Nederkoorn PJ, Brown MM. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial [published correction appears in Lancet. 2010;376:90]. Lancet. 2010;375:985 997. 430. Bonati LH, Fraedrich G; Carotid Stenting Trialists Collaboration. Age modifies the relative risk of stenting versus endarterectomy for symp- tomatic carotid stenosis: a pooled analysis of EVA-3S, SPACE and ICSS. Eur J Vasc Endovasc Surg. 2011;41:153 158. 431. Carotid Stenting Trialists Collaboration;Bonati LH, Dobson J, Algra A, Branchereau A, Chatellier G, Fraedrich G, Mali WP, Zeumer H, Brown MM, Mas JL, Ringleb PA. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta- analysis of individual patient data. Lancet. 2010;376:1062 1073. 432. Howard VJ, Lutsep HL, Mackey A, Demaerschalk BM, Sam AD 2nd, Gonzales NR, Sheffet AJ, Voeks JH, Meschia JF, Brott TG; CREST Investigators. Influence of sex on outcomes of stenting versus endarterec- tomy:asubgroupanalysisoftheCarotidRevascularizationEndarterectomy versus Stenting Trial (CREST). Lancet Neurol. 2011;10:530 537. 433. Voeks JH, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC 3rd, Aronow HD, Eskandari MK, Sheffet AJ, Lal BK, Meschia JF, Brott TG; CREST Investigators. Age and outcomes after carotid stenting and endarterectomy: the Carotid Revascularization Endarterectomy Versus Stenting Trial. Stroke. 2011;42:3484 3490. 434. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/ SNIS/SVM/SVS guideline on the management of patients with extra- cranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery [published corrections appear in Stroke. 2012;43:e80 and Stroke. 2011;42:e542]. Stroke. 2011;42:e464 e540. 435. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293 1304. 436. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials [published correction appears in JAMA. 2006;295:2002]. JAMA. 2006;295:306 313. 437. Antithrombotic Trialists (ATT) Collaboration; Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collabora- tive meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849 1860. 438. D Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743 753. 439. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score [published correction appears in JAMA. 2007;297:1433]. JAMA. 2007;297:611 619. 440. D Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk pro- file: adjustment for antihypertensive medication: the Framingham Study. Stroke. 1994;25:40 43. 441. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S.A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol. 2002;55:129 136. 442. Bineau S, Dufouil C, Helmer C, Ritchie K, Empana JP, Ducimeti re P, Alp rovitch A, Bousser MG, Tzourio C. Framingham stroke risk func- tion in a large population-based cohort of elderly people: the 3C study. Stroke. 2009;40:1564 1570. 443. Moons KG, Bots ML, Salonen JT, Elwood PC, Freire de Concalves A, Nikitin Y, Sivenius J, Inzitari D, Benetou V, Tuomilehto J, Koudstaal PJ, Grobbee DE. Prediction of stroke in the general population in Europe (EUROSTROKE): is there a role for fibrinogen and electrocardiogra- phy? J Epidemiol Community Health. 2002;56(suppl 1):i30 i36. 444. Tanne D, Yaari S, Goldbourt U. Risk profile and prediction of long-term ischemic stroke mortality: a 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. Circulation. 1998;98:1365 1371. 445. Chambless LE, Heiss G, Shahar E, Earp MJ, Toole J. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study [published correction appears in Am J Epidemiol. 2004;160:927]. Am J Epidemiol. 2004;160:259 269. 446. Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, de Girolamo G, Haro JM, Jin R, Karam EG, Kovess-Masfety V, Levinson D, Medina Mora ME, Ono Y, Ormel J, Pennell BE, Posada-Villa J, Sampson NA, Williams D, Kessler RC. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry. 2009;66:785 795. 447. Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, Rossouw JE, Wassertheil-Smoller S, Ridker PM. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women s Health Initiative. Circulation. 2012;125:1748 1756. 448. Wassertheil-Smoller S, McGinn A, Allison M, Ca T, Curb D, Eaton C, Hendrix S, Kaplan R, Ko M, Martin LW, Xue X. Improvement in stroke risk prediction: role of C-reactive protein and lipoprotein-associated phos- in the Women s Health Initiative. Int J Stroke. October 23, 2012. doi:10.1111/j.1747-4949.2012.00860.x. http://onlinelibrary.wiley. 2013. 449. Hermes W, Franx A, van Pampus MG, Bloemenkamp KW, van der Post JA, Porath M, Ponjee G, Tamsma JT, Mol BW, de Groot CJ. 